Switching to monthly berobenatide to keep weight off in adults with overweight or obesity
Tests monthly berobenatide in adults with obesity who already lost weight on semaglutide or tirzepatide.
Plain-language title generated from the registry record
Registry title: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Key facts
- Where
- Botany and Camberwell, AustraliaSee the 2 sites
- Phase
- Phase 3
Where in Australia
- Emeritus Research SydneyBotany, AustraliaNot yet recruiting
- Emeritus Research CamberwellCamberwell, AustraliaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07845500
- Record updated
- 5 November 2026
- Original description
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.Read full original descriptionShow less
A PHASE 3 STUDY TO EVALUATE THE SWITCH TO MONTHLY BEROBENATIDE FOR MAINTAINING WEIGHT IN ADULTS WHO ARE ON WEEKLY SEMAGLUTIDE OR TIRZEPATIDE (VESPER-SWITCH)
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.
Participants will be in the study for about 11 months.
Inclusion: Aged ≥18 years; Currently taking semaglutide or tirzepatide for obesity management.
Exclusion: Diagnosis of any form of diabetes; History of acute or chronic pancreatitis; Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).